Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial
概览
- 阶段
- 4 期
- 干预措施
- Control
- 疾病 / 适应症
- Ulcerative Colitis
- 发起方
- Post Graduate Institute of Medical Education and Research, Chandigarh
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Reduction of at least 3 points in the D.A.I i.e. Reduction in the activity score of inflammation from the baseline value at 12 weeks.
- 最后更新
- 14年前
概览
简要总结
Intestinal inflammation seen in inflammatory bowel disease (IBD) results from an altered mucosal immune response to luminal bacterial antigens. Current research suggests that an inappropriate and persistent immune response against commensal intestinal bacterial flora plays a pivotal role in the pathogenesis of chronic Inflammatory Bowel Disease (IBD). It has been also proposed that the signs and symptoms of IBD may be mediated by the increased intestinal permeability secondary to low grade inflammation in the gut mucosa. Increased intestinal permeability results in further exposure of underlying intestinal mucosa to luminal bacteria and antigens perpetuating the intestinal inflammation. Thus restoring intestinal permeability rather than only reduction of mucosal inflammation would thus be a desirable endpoint in the restoration of mucosal integrity and would be the harbinger of better long term outcome. Many clinical trials have shown that probiotics may have beneficial effect on IBD patients. Probiotics are hypothesized to work by several mechanisms though they are not clearly established. The role of probiotics in improving intestinal permeability has not been evaluated. The probiotic VSL #3 is easily available, cheap, effective and safe alternative or substitute for the existing therapeutic agents will be evaluated in this study for their efficacy, tolerability, compliance in inducing clinical response in patients with Ulcerative colitis. This will be a double blind randomized placebo controlled study to determine the clinical efficacy of 12 weeks of oral probiotics (VSL#3) in patients with inflammatory bowel disease. The objectives of this study are to determine the efficacy of probiotics on clinical endoscopic and histological improvement, to find the improvement in faecal, serum and intestinal tissue inflammatory markers, improvement in intestinal permeability, improvement in Quality of life parameters.
研究者
Dr. Bikash Medhi, MBBS, MD(AIIMS),MAMS,FIMSA
Additional Professor, Department of Pharmacology
Post Graduate Institute of Medical Education and Research, Chandigarh
入排标准
入选标准
- •Age between 18 and 65 years
- •Active disease at presentation
排除标准
- •Pregnant or lactating women
- •Any patient who has received probiotic in the preceding 4 weeks
- •Patient with life threatening cardiac, renal, pulmonary or cardiovascular disease
- •Inability to obtain the informed consent
- •Severe disease requiring hospitalization / steroids/ anti-cytokine therapy
- •Patient taking aspirin and other antiplatelet drugs
- •Patient with uncontrolled diabetes
- •Patient with Gall stone disease
- •Patient currently on antibiotic,NSAIDs or indigenous medicine
研究组 & 干预措施
Control
干预措施: Control
Probiotic
干预措施: Probiotic
结局指标
主要结局
Reduction of at least 3 points in the D.A.I i.e. Reduction in the activity score of inflammation from the baseline value at 12 weeks.
时间窗: 12 weeks
次要结局
- Reduction in faecal and serum inflammatory markers(12 weeks)
- Reduction in intestinal permeability(12 weeks)